Market Performance of F5, Inc. (FFIV)
F5, Inc. (ticker FFIV) closed 1.86 % lower on the trading day that ended at 04:24 PM Central Europe on Friday, 23 October 2026.
- Current trading price: USD 454.04
- Shares outstanding: 56.6 million
- Market capitalization: USD 26 billion
- Volume traded in last 24 h: USD 222.4 million
- Month‑to‑date performance: down 1.30 % since the end of September
- 200‑day simple moving average: USD 359.12
- 52‑week high: USD 483.30 (12 October 2026)
- 52‑week low: USD 223.76 (19 November 2025)
Recent Performance of Related Stocks
| Symbol | 24‑hr change | Current price (USD) | Market cap (USD bn) | P/E ratio |
|---|---|---|---|---|
| ALNY | +0.97 % | 223.79 | 30.1 | 38.31 |
| EME | –5.54 % | 648.08 | 30.8 | 21.75 |
| ON | –4.82 % | 72.04 | 30.0 | 49.61 |
| DXCM | –2.42 % | 78.81 | 30.3 | 31.84 |
Highlights of Related Companies
Alnylam (ALNY) Alnylam’s stock rose 0.97 % in the last 24 hours, now trading at USD 223.79. The company’s market capitalization is USD 30.1 billion, and its price‑to‑earnings ratio is 38.31.
BB Biotech AG BB Biotech reported a positive third‑quarter performance, with net asset value growth and share price outperformance relative to the Nasdaq Biotechnology Index. The company recorded a net profit for the quarter and improved earnings trajectory for the first nine months of 2026 versus the same period a year earlier. Three portfolio companies achieved U.S. drug approvals. Acquisitions of Crinetics Pharmaceuticals (by Vertex) and Nuvalent (by GSK) were completed, and proceeds were redeployed within the quarter. BB Biotech added twelve new positions and exited eight, maintaining a portfolio of 43 companies and narrowing the discount between share price and NAV. The firm continues to develop its AI‑driven investment system, integrating scientific evidence, clinical milestones, and valuation assumptions.
SaludMedical Inc. SaludMedical, after its 2025 IPO, reported strong first fiscal year results. The Evoke® System closed‑loop neuromodulation platform gained traction, with increased physician adoption and patient implant rates in the U.S. and abroad. FDA approval of the CAP24 paddle lead expanded the product portfolio into surgical paddle‑lead procedures. The company achieved revenue growth that surpassed guidance, improved gross margin performance, and generated operating cash above expectations. Management emphasized continued investment in commercial infrastructure and product development while maintaining focus on operating leverage and disciplined capital allocation.
About F5, Inc.
F5, Inc. is a U.S.‑based company that provides integrated internet traffic management solutions. The company offers software‑based solutions and manages, controls, and optimizes internet traffic and content. F5 also delivers internet content automatically to service providers and e‑businesses worldwide.
